Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Clinical translation of controlled protein delivery systems for tissue engineering

Spiller KL., Vunjak-Novakovic G.

Clinical Trial, published in Drug Deliv Transl Res (2015) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Drug Deliv Transl Res (2015)
Reported sample size
—
Source database
Europe PMC
PMID
25787736
PMCID
PMC4311895
DOI
10.1007/s13346-013-0135-1
Citations
32

Abstract (original English)

Strategies that utilize controlled release of drugs and proteins for tissue engineering have enormous potential to regenerate damaged organs and tissues. The multiple advantages of controlled release strategies merit overcoming the significant challenges to translation, including high costs and long, difficult regulatory pathways. This review highlights the potential of controlled release of proteins for tissue engineering and regenerative medicine. We specifically discuss treatment modalities that have reached preclinical and clinical trials, with emphasis on controlled release systems for bone tissue engineering, the most advanced application with several products already in clinic. Possible strategies to address translational and regulatory concerns are also discussed.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansProteinsDelayed-Action PreparationsDrug Delivery SystemsTissue EngineeringTissue Scaffolds

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.